Year: 2023

Amanda Pegmatites MapAmanda Pegmatites MapMONTREAL, Oct. 18, 2023 (GLOBE NEWSWIRE) — Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or “The Company”) announces the start of a ten-day prospecting program on the Amanda project. The team, composed of a geologist and two technicians, will revisit, and sample the different pegmatites listed in previous years by the Ministry of Natural Resources and Forests (MRNF) and Vanstar Mining Resources Inc. Different pegmatites known on the Amanda project were also intersected in several historical drillings carried out from 1997 to 2010 but no analysis was done to verify the presence of lithium in them. The technical team will therefore try to find these old drillings and take, if possible, several samples for analysis. The Company plans to take a few hundred samples from the various...

CERRITOS, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) — The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that the company will release its third quarter 2023 financial results after the market close on Wednesday, November 8, 2023, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13741314. The replay will be available until November 15, 2023. Interested investors and other parties may also listen to a simultaneous...

Over 300 partners, customers, industry leaders join Lightspeed’s executive team for three days of informative sessions, insightful panelists, exciting updates and moreUnlocking The Future of Commerce at Lightspeed Oxygen SummitExplore groundbreaking sessions and industry-shaping panels at the upcoming summit in Montreal.MONTREAL, Oct. 18, 2023 (GLOBE NEWSWIRE) — Lightspeed Commerce Inc. (NYSE | TSX: LSPD) plans to welcome over 300 independent business owners, partners and Lightspeed leaders from around the world to the Lightspeed Oxygen Summit, an invitation-only three-day conference in the heart of Montreal. Powering the world’s best businesses, Lightspeed is the unified POS and payments platform for ambitious entrepreneurs who wish to accelerate growth, provide the best customer experiences and become a go-to destination...

MISSISSAUGA, Ontario, Oct. 18, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce the launch of menopauseinformation.ca, a comprehensive online platform designed to empower peri-menopausal and menopausal women across Canada.   Menopause is a natural transition that every woman experiences, and understanding this transition is crucial for a smoother journey. The menopauseinformation.ca website aims to provide vital information and resources to help women navigate through this transition with confidence. By being informed, women can engage in more effective discussions with their healthcare providers, leading to better-managed menopause experiences. This platform offers a wealth of up-to-date information including expert insights from trusted Canadian menopause doctors, frequently asked questions,...

The 24,000-square-foot facility includes new high-voltage and E-Mobility labs, as well as technical training rooms for automotive clients to develop and optimize designs CHANDLER, Ariz., Oct. 18, 2023 (GLOBE NEWSWIRE) — The automotive industry is evolving at a rapid pace, with E-Mobility and Advanced Driver Assistance Systems (ADAS) driving the market’s need for innovative solutions. Microchip Technology (Nasdaq: MCHP), a leading provider of smart, connected and secure embedded control solutions, today announces the expansion of its Detroit Automotive Technology Center in Novi, Michigan. The 24,000-square-foot facility is the destination for automotive clients to explore new technologies and to meet with technical experts to get support for their end applications and designs. Microchip has been part of the Detroit community since...

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 18, 2023 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Edward L. Williams to its Board of Directors. “We are pleased to welcome Eddie to our Board of Directors,” said Jonathan Solomon, Chief Executive Officer of BiomX Inc. “As a seasoned executive with extensive board experience, Eddie has successfully led the commercialization and marketing efforts across multiple therapeutic categories for global pharmaceutical companies. His insights, advice and experience will undoubtedly help guide BiomX as we further advance our products in the clinic and towards the market.” Mr. Williams is a well-recognized, senior global...

Project seeks to decarbonize asphalt production DANBURY, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) — FuelCell Energy, Inc. (Nasdaq: FCEL) has been contracted by EDF Energy for a project exploring the viability of using hydrogen to decarbonize asphalt production. The Bay Hydrogen Hub consortium, which is made up of EDF, Heidelberg UK, the National Nuclear Laboratory, and Vulcan Burners, proposes combining the use of FuelCell Energy’s 1-Megawatt Solid Oxide Electrolyzer Cell (SOEC) with nuclear generated heat and electricity to produce hydrogen in bulk at a lower cost than other hydrogen electrolysis technologies. FuelCell Energy President and CEO Jason Few commented, “Solid oxide electrolysis is ideal for producing hydrogen from nuclear power sources. The already high efficiency of solid oxide electrolysis systems can be raised even...

Frost & Sullivan recognizes Adial for its best practices in precision medicine for the addiction disorders industryAdial Pharmaceuticals Wins Frost & Sullivan’s 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership AwardFrost & Sullivan recognizes Adial for its best practices in precision medicine for the addiction disorders industryCHARLOTTESVILLE, Va., Oct. 18, 2023 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has been awarded the 2023 Best Practices Technology Innovation Leadership Award in the North American precision medicine for addiction disorders...

GUELPH, Ontario, Oct. 18, 2023 (GLOBE NEWSWIRE) — Current Water Technologies Inc. (TSX-V: WATR) (“CWTI” or “the Company” or “the Corporation”) is a global leader in the development of novel electrochemical technology for the treatment of ammonia in the municipal and industrial waste water sectors and in the development of an international Green Hydrogen network. CWTI is pleased to provide our shareholders and supporters with the following corporate update. Marketing Activities 2023 has been a transistional year for CWTI with the establishment of a sales and marketing team that is engaging numerous domestic and international parties in the oil & gas, municipal, agricultural, fertilizer, biogas, and mining sectors. Management believes the future is bright for our innovative AmmEL-H2 technology...

CB-012 allogeneic anti-CLL-1 CAR-T cell therapyCB-012, a genome-edited allogeneic anti-CLL-1 CAR-T cell therapy with both checkpoint disruption and immune cloaking— AMpLify Phase 1 clinical trial to initiate patient enrollment by mid-2024 — — CB-012 is the first allogeneic CAR-T cell therapy with both checkpoint disruption and immune cloaking to enter the clinic — BERKELEY, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-012, an allogeneic anti-C-type lectin-like molecule-1 (anti-CLL-1) CAR-T cell therapy. CB-012 will be evaluated in the multicenter,...